U.K. official sacked over drug lobbying case; Lupin launches generic of Janssen birth control pills in U.S.;

@FiercePharma: Study finds some docs are not strongly recommending HPV vaccines for preteens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. Article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Former Valeant CFO Schiller to step in for hospitalized CEO Pearson. Report | Follow @CarlyHFierce

> Isle of Wight health official Paul Jerram has been terminated after an investigation into reports that he was tied to drug companies lobbying NHS staff. Story

> The FDA has posted the warning letter that India's Cadila Healthcare acknowledged last week it had received. Post

> Lupin Pharmaceutical has launched in the U.S. a generic of Janssen's Ortho Tri-Cyclen Lo birth control tablets. Story

> A broad review of health records found no indication that the children of women who take antidepressants during pregnancy are at a higher risk of having autism and related disorders or attention-deficit hyperactivity disorder (ADHD). Report

Medical Device News

@FierceMedDev: Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: This question has been on my mind for a while. What does the "F" in F. Michael Ball stand for? More | Follow @EmilyWFierce

@VarunSaxena2: Medtronic CEO ambivalent about competing with Google, despite budding robotic surgery rivalry. FierceMedicalDevices story | Follow @VarunSaxena2

> Brain app startup settles with FTC over false product claims. Article

> Benvenue secures $60M in debt and equity to accelerate commercialization of its spinal implants. More

> NEA partner outlines challenging med tech VC landscape heading into 2016. Editor's corner

Biotech News

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Vtesse gets a BTD on Niemann Pick drug. Release | Follow @JohnCFierce

@DamianFierce: man with lots of money has no regrets about making more of it. More from Bloomberg | Follow @DamianFierce

> Accelerator's $48M biotech project looks to spark the NYC startup scene. Report

> Merck bets up to $595M on Quartet's chronic pain pipeline. News

> Biogen backs Rodin's Alzheimer's efforts in a $500M deal. Story

> Conatus pops on more incremental liver data for its lead drug. Article

Biotech Research News

> Cannabinoid drug reduces epileptic seizures in hard-to-treat children. Item

> CRISPR/Cas9 trifecta: Researchers correct genetic defect that triggers Duchenne muscular dystrophy. Report

> Mayo Clinic researchers tackle age-related stem cell dysfunction and metabolic disease. More

> Gut bacteria plays a big role in regulating impact of anti-inflammatory NSAIDs. Story

> UNC team spotlights Dicer as a new target for brain cancers. Article

Vaccines News

> Study finds some docs are not strongly recommending HPV vaccines for preteens. More

> Bavarian Nordic files for Nasdaq IPO. News

> Emergex to use Midatech nanoparticle tech for vaccines against infectious diseases. Story

> Norway's Bionor tests drug-vaccine combo against HIV. Item

> China approves Sinovac's vaccine for hand, foot and mouth disease. Article

Pharma Marketing News

> Actelion slaps $160K-plus price tag on new PAH med Uptravi. Item

> Native advertising for pharma: Winning format or slippery slope to regulatory headaches? Report

> Boosted by CV data, Lilly's Jardiance grabs market share from J&J, AZ. Story

> FDA sends fewer drug promotion action letters in 2015--but is that a good thing for pharma? More

> Novartis matches respiratory rivals with 'smart inhaler' collaboration. Article

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.